相关实验视频

Updated: Jul 16, 2025

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

遗传学在耐火性免疫性血栓塞细胞减小症中的作用

James L Zehnder¹, James B Bussel², Nichola Cooper³

¹Department of Pathology and Medicine, Stanford University School of Medicine, Stanford, California, USA.

British journal of haematology

|September 22, 2023

概括

耐火性免疫性血栓缩症 (rITP) 导致严重的健康问题. 本综述探讨了潜在的遗传或获得突变,如细胞毒性T细胞扩张,有助于rITP折射性,并指导新的治疗方法.

科学领域:

血液学血液学血液学
免疫学免疫学免疫学
遗传学是一个遗传学.

背景情况:

耐药性免疫性血小板缺血症 (rITP) 与患者发病率和死亡率的增加有关.
目前对rITP折射性的理解是有限的,这阻碍了针对性的治疗方法的开发.
病变发生通常被认为是遗传倾向和环境因素的结合,尽管家族病例很少见.

研究的目的:

审查对rITP遗传遗传原因的证据.
探索获得突变的作用,特别是细胞毒性T细胞的克隆扩张,在rITP折射性.
确定潜在的标记物,以指导rITP的新疗法选择.

主要方法:

关于免疫血小板缩病因的研究的文献综述.
对导致疾病折射性的遗传和免疫因素的分析.
探索细胞毒性T细胞在自身免疫性疾病中的参与.

主要成果:

有证据表明,由于家族病例的罕见性和双胞胎研究,rITP的简单遗传遗传原因不太可能.
遗传突变可以为自身免疫性疾病提供背景,可能包括rITP.
获得的突变,特别是导致细胞毒性T细胞的克隆扩张的突变,被认为是rITP的重要因素.

结论:

了解rITP折射性的具体原因对于开发有效的治疗方法至关重要.
对获得突变和细胞毒性T细胞动态的进一步研究可能会为rITP揭示新的治疗点.
识别可折射性的生物标志物可以为免疫性血小板的患者个性化治疗策略.

关键词:

遗传学遗传学遗传学是一个疾病发病率疾病发病率疾病发病率耐火性免疫性血小板缩症

更多相关视频

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...